Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the response rate, complete and partial, of patients with indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Any low-grade B-cell, CD20 positive, non-Hodgkin's lymphoma that is felt to otherwise be a transplant candidate (relapsed, induction failure, first PR or CR). Specifically: Small lymphocytic, marginal zone, mantle cell, and follicular histologies.

• At least 19 years of age

• Signed written informed consent

• Expected survival of at least 6 months

• Subjects with out history of T-cell lymphoma

• WHO performance status greater or equal to 2

• Subjects without serious disease or condition that, in the opinion of the investigator, would compromise the subject's ability to participate in the study.

• Non-pregnant and non-lactating women

• Male or female subjects of reproductive potential who are able to follow accepted birth control measures.